UPDATE 1-SpringWorks’ non-cancerous tumor drug to be priced at $29,000 per month in US

SpringWorks Therapeutics' drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the company said on a conference call on Tuesday. H.C. Wainwright analyst Robert Burns expected the drug to be priced at around $18,000 per month. TD Cowen analyst Yaron Werber expected the price to be $247,000 for 12 months, which leads to the per-month price of around $20,583.